- Policy
- Drugs caught in rebates for 2 years can be replaced by fines
- by Kim, Jung-Ju Aug 26, 2021 05:58am
- Among the insurance drugs caught as rebates, drugs that have been claimed for two consecutive years based on the date of disposal are expected to be replaced by fines. It belongs to cases that may cause inconvenience in patient care, not to harm public welfare. In the case of fines on these drugs, the rate will be increased by varying the upp
- Policy
- Will the voluntary recovery of AZBT be expanded?
- by Lee, Tak-Sun Aug 25, 2021 05:57am
- More and more drugs are voluntarily recovered due to the excessive detection of impurities AZBT(Azido Methyl Bipheny Ttetrazole). On the 6th, the recovery of items produced before 2021 among three items containing Irvesartan (Rovelito, CoAprovel, and Arovel) was decided, and AZBT was also detected in a Valsartan compound produced by a domesti
- Policy
- Opdivo's benefit extends for kidney cancer & parietal cancer
- by Lee, Hye-Kyung Aug 25, 2021 05:57am
- As domestic No. 1 immuno-cancer drug "Opdivo (Nivolumb)" renewed its contract with RSA, the benefit standard has also been expanded. The HIRA will issue a "proposal to revise the announcement of drugs prescribed and dispensed to cancer patients" and will inquire about their opinions by the 25th. If there is no disagreement, the benefit will b
- Policy
- Janssen’s acetaminophen tablets may replace Tylenol
- by Lee, Tak-Sun Aug 24, 2021 06:06am
- Janssen Korea, which locally manufactures and sells Tylenol in Korea, has received import authorization for its product. The company is presumed to be making the move to secure alternatives in advance before stopping the operation of its Hyangnam plan at the end of this year. On the 23rd, the Ministry of Food and Drug safety approved Jan
- Policy
- The effectiveness of NIP expansion policy?
- by Aug 24, 2021 06:05am
- Moon Jae-in president announced to expand under the age of 17 for vaccine against cervical cancer vaccination for free, while the few people seemed to be criticizing as 'show off'. President Moon said he would expand the vaccination target from the age of 12 to the age of 17 to mark the 4th anniversary of the petition. In the past, peo
- Policy
- Over 40mil COVID-19 vaccines cleared for release in 6 mos
- by Lee, Tak-Sun Aug 23, 2021 05:55am
- The number of COVID-19 vaccines granted National Lot Release in Korea has exceeded 40 million. The large-scale batches of Pfizer vaccines introduced in late July have accelerated the number of vaccines approved for lot release. According to the Ministry of Food and Drug Safety on the 22nd, 1.6 million doses (for 800 thousand people) Pfize
- Policy
- Perjeta's price was down 10% to ₩2,214,600
- by Kim, Jung-Ju Aug 23, 2021 05:55am
- Five drugs that succeeded in insurance benefits in Korea due to Risk Sharing Agreement (RSA) have been re-contracted by lowering drug prices to the expiration of the contract. According to the industry, the MOHW is recently pushing to revise the list of drug benefits aimed at the 1st of next month for a total of five successful drugs negotia
- Policy
- AstraZeneca vaccine has been approved in 121 countries
- by Lee, Tak-Sun Aug 23, 2021 05:55am
- The most widely approved coronavirus vaccine in countries around the world was AZD1222, co-developed by AstraZeneca and Oxford University. AZ vaccine was the first approved COVID vaccine in Korea in February. According to the MFDS, the KOBIA, abd the national vaccine safety technology support center, AZ vaccine was approved in 121 countries a
- Policy
- Women under the age of 17 will be given Gardasil 9 for free
- by Lee, Jeong-Hwan Aug 23, 2021 05:55am
- President Moon Jae-in is answering directly to celebrate the 4th anniversary of the petition. He promised the government will expand the scope of free cervical cancer vaccinations from women under the current age of 12 to under the age of 17 so that all women and teenagers can receive free vaccination benefits. He said he would also make ef
- Policy
- Lyrica CR generics begin development...PMS expires next July
- by Lee, Tak-Sun Aug 20, 2021 05:56am
- Development for generics of Pfizer’s pain reliever ‘Lyrica CR,’ whose post-market surveillance (PMS) period expires in July next year, has begun. Unlike Lyrica, which is taken twice a day, Lyrica CR is a once-daily formulation and is used for peripheral neuropathic pain in adults. With more than 80 pharmaceutical companies participatin
